However, the resistance to imatinib develops in significant portions of patients under treatment, especially in those with CML in advanced stages or with Ph+ ALL, mostly due to the emergence of mutations in the BCR/ABL kinase domain. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.